

| <b>Alert</b>                                |   |   |          |                           |                |                           |             |                       |                |                       |            |
|---|---|---|----------|---------------------------|----------------|---------------------------|-------------|-----------------------|----------------|-----------------------|------------|
| <b>Indication</b>                           | Heart failure.<br>Fluid overload.<br>Short-term treatment in infants with or developing chronic lung disease.<br>Oliguric renal failure.<br>Diuresis renography.  |   |          |                           |                |                           |             |                       |                |                       |            |
| <b>Action</b>                               | Potent loop diuretic. Inhibits sodium and chloride absorption in the ascending limb of the loop of Henle and in the proximal and the distal tubules.<br>Furosemide causes urinary losses of water, sodium (increases fractional excretion of sodium by 20–25%), <sup>2</sup> potassium and chloride. Urinary losses of calcium and magnesium and urinary pH are increased.  |   |          |                           |                |                           |             |                       |                |                       |            |
| <b>Drug type</b>                            | Loop diuretic.  |   |          |                           |                |                           |             |                       |                |                       |            |
| <b>Trade name</b>                           | IV: Lasix Solution for Injection, Lasix High Dose Concentrate for Infusion, Furosemide-Baxter Solution for Injection.<br>Oral: Lasix Oral Solution (refrigerated), Lasix Oral Solution (not requiring refrigeration).   |   |          |                           |                |                           |             |                       |                |                       |            |
| <b>Presentation</b>                         | IV: 20 mg/2 mL, 40 mg/4 mL or 250 mg/25 mL ampoule.<br>Oral: 10 mg/mL, 30 mL bottle.<br>Note: Commercial preparation “Lasix Oral Solution (not requiring refrigeration)” contains 12.7% v/v alcohol.<br>Non-alcohol containing suspension can be compounded by local pharmacy.  |   |          |                           |                |                           |             |                       |                |                       |            |
| <b>Dose</b>                                 | <p><b>IV or PO*</b>: 1 to 2 mg/kg/dose.<br/>Dose interval</p> <table border="1" style="width: 100%;"> <thead> <tr> <th>Corrected gestational age/Postmenstrual age</th> <th>Interval</th> </tr> </thead> <tbody> <tr> <td>Preterm infant &lt; 34 weeks</td> <td>Every 24 hours</td> </tr> <tr> <td>Preterm infant ≥ 34 weeks</td> <td>12–24 hours</td> </tr> <tr> <td>Term infant 0–30 days</td> <td>Every 12 hours</td> </tr> <tr> <td>Term infant &gt; 30 days</td> <td>8–12 hours</td> </tr> </tbody> </table> <p>*PO: Dose may be increased up to maximum 6 mg/kg/dose in term infants with heart failure.</p> <p><b>IV Infusion</b>: 0.05 to 0.2 mg/kg/hour (approximately 1-5 mg/kg/day).<br/>Dose may be increased to maximum 0.4 mg/kg/hour on the advice of the renal physician.</p> <p>Diuresis renography: 1 mg/kg stat.</p> | Corrected gestational age/Postmenstrual age | Interval | Preterm infant < 34 weeks | Every 24 hours | Preterm infant ≥ 34 weeks | 12–24 hours | Term infant 0–30 days | Every 12 hours | Term infant > 30 days | 8–12 hours |
| Corrected gestational age/Postmenstrual age | Interval  |   |          |                           |                |                           |             |                       |                |                       |            |
| Preterm infant < 34 weeks                   | Every 24 hours  |   |          |                           |                |                           |             |                       |                |                       |            |
| Preterm infant ≥ 34 weeks                   | 12–24 hours   |   |          |                           |                |                           |             |                       |                |                       |            |
| Term infant 0–30 days                       | Every 12 hours  |   |          |                           |                |                           |             |                       |                |                       |            |
| Term infant > 30 days                       | 8–12 hours  |   |          |                           |                |                           |             |                       |                |                       |            |
| <b>Dose adjustment</b>                      |   |   |          |                           |                |                           |             |                       |                |                       |            |
| <b>Maximum dose</b>                         | IV: 2 mg/kg/dose<br>IV infusion: 0.4 mg/kg/hour<br>Oral: 6 mg/kg/dose   |   |          |                           |                |                           |             |                       |                |                       |            |
| <b>Total cumulative dose</b>                |   |   |          |                           |                |                           |             |                       |                |                       |            |
| <b>Route</b>                                | IV or oral  |   |          |                           |                |                           |             |                       |                |                       |            |
| <b>Preparation</b>                          | <p>IV bolus: Give undiluted. If dilution required draw up 0.5mL (5 mg of furosemide) and add 9.5mL sodium chloride 0.9% to make a final volume of 10 mL with a concentration of 0.5 mg/mL.</p> <p>IV infusion:<br/>Single-strength infusion: Draw up 0.5 mL/kg (5 mg/kg of furosemide) and make up to 10 mL with sodium chloride 0.9% or glucose 5% or glucose 10% or glucose 20% to make a 0.5 mg/kg/mL solution. Infusing at a rate of 0.1 mL/hour = 0.05 mg/kg/hour.</p> <p>Double-strength infusion: Draw up 1 mL/kg (10 mg/kg of furosemide) and make up to 10 mL with sodium chloride 0.9% or glucose 5% or glucose 10% or glucose 20% to make a 1 mg/kg/mL solution. Infusing at a rate of 0.1 mL/hour = 0.1 mg/kg/hour.</p> <p>Oral: Use as supplied undiluted.</p>   |   |          |                           |                |                           |             |                       |                |                       |            |
| <b>Administration</b>                       | <p>IV bolus over 2–4 minutes: maximum rate not to exceed 0.5 mg/kg/minute or 4 mg/minute. For diuresis renography – dose should be given as a push.<sup>1</sup></p> <p>IV infusion: Via syringe pump</p> <p>Oral: Solution may be administered without regard to feeds.</p>   |   |          |                           |                |                           |             |                       |                |                       |            |

|                          |  |
|--------------------------|--|
| <b>Monitoring</b>        | Urine output, weight, serum sodium and potassium. Screening for nephrocalcinosis may be required for preterm infants on prolonged therapy.   |
| <b>Contraindications</b> | Known hypersensitivity to furosemide or sulfonamides or any of the inactive ingredients.<br>Severe hypokalaemia, hyponatraemia, hypovolaemia, dehydration or hypotension must be regarded as contraindications until serum electrolytes, fluid balance and blood pressure have been restored to normal levels.<br>Severe jaundice at risk of bilirubin encephalopathy.   |
| <b>Precautions</b>       | Commercially available oral furosemide solution contains ethanol and 2 mg/kg/day of solution equates to 1.4 mL/kg/week ethanol intake [equivalent to 1 unit alcohol/week for a man weighing 70 kg].<br>If increasing azotaemia and oliguria occur during treatment of severe progressive renal disease, discontinue furosemide.<br>Jaundice – furosemide may displace bilirubin from albumin. However, bilirubin displacement is negligible with standard doses.<br>Renal calcifications have occurred in some severely premature infants treated with intravenous Lasix for oedema due to patent ductus arteriosus and hyaline membrane disease. The concurrent use of chlorothiazides has been reported to decrease hypercalciuria and to dissolve some calculi.   |
| <b>Drug interactions</b> | Furosemide can cause the depletion of potassium and magnesium, which can predispose patients to serious cardiac arrhythmias, particularly in the presence of digitalis therapy.<br>The risk of electrolyte depletion is markedly enhanced when 2 diuretics are used in combination.<br>May prolong action of muscle relaxants.<br>Avoid concomitant usage of aminoglycosides to avoid ototoxicity.<br>Anticonvulsants may decrease the response to furosemide (frusemide). Use of furosemide (frusemide) concomitantly with chloral hydrate is not recommended.  |
| <b>Adverse reactions</b> | Furosemide is associated with renal losses of calcium, sodium, chloride and potassium.<br>Prolonged and higher doses of furosemide are associated with ototoxicity and nephrocalcinosis.   |
| <b>Compatibility</b>     | Fluids: Glucose 5%, glucose 10%, glucose 20%, sodium chloride 0.9%.<br>Y-site <sup>24,25</sup> : Aciclovir, alprostadil, amikacin, amphotericin B lipid complex, amphotericin B liposome, atenolol, atropine, aztreonam, benzylpenicillin, calcium chloride, calcium gluconate, cefazolin, cefepime, cefotaxime, ceftazidime, ceftriaxone, chloramphenicol sodium succinate, chlorothiazide, clindamycin, cloxacillin, dexamethasone, dexmedetomidine, digoxin, enalaprilat, epinephrine, epoetin alfa, fentanyl, folic acid, fosphenytoin, ganciclovir, heparin, hydrocortisone sodium succinate, ibuprofen lysine, imipenem-cilastatin, indomethacin, lidocaine, linezolid, meropenem, methylprednisolone sodium succinate, metoprolol, metronidazole, naloxone, nitroprusside sodium, octreotide, pamidronate, pentobarbital, phenobarbital, piperacillin-tazobactam, potassium acetate, potassium chloride, propofol, propranolol, ranitidine, sodium acetate, sodium bicarbonate, succinylcholine, ticarcillin-clavulanate, tobramycin, urokinase, voriconazole.<br><b>Variable compatibility:</b> Amiodarone, Amphotericin B conventional colloidal, ampicillin, azithromycin, dobutamine, dopamine, erythromycin lactobionate, fluconazole, gentamicin, hydralazine, insulin, labetalol, magnesium sulfate, midazolam, morphine, nitroglycerin, norepinephrine, pantoprazole, phenylephrine, remifentanyl, thiopental, vasopressin. |
| <b>Incompatibility</b>   | Fluids: No information. Variable compatibility with parenteral nutrition solutions.<br>Do not mix furosemide with solutions that have a pH of less than 5.5.<br><br>Y-site <sup>24,25</sup> : Atracurium, caffeine citrate, diazepam, diazoxide, filgrastim, glycopyrronium, hyaluronidase, ketamine, milrinone, pancuronium, phenytoin, protamine, pyridoxine, rocuronium, sulfamethoxazole-trimethoprim, thiamine, vancomycin, vecuronium, verapamil.  |
| <b>Stability</b>         | Do not use if solution is discoloured.<br>Diluted IV solution: Stable for 24 hours at 2–25°C (preferred storage is 2-8°C).<br>Oral solution:<br>Commercial preparation “Lasix”- Discard 8 weeks after opening.<br>Compounded suspension – check with local Pharmacy.   |
| <b>Storage</b>           | Ampoule: Store below 25°C. Protect from light.<br>Occasionally crystal deposits may be seen when ampoules are stored at low temperatures. Dissolve crystals by warming to 40°C and injection may be used. Discard solutions that are yellow.<br><br>Oral solution:<br>Commercial preparation – refer to product label for instructions regarding storage conditions.   |

|                         |  |
|-------------------------|--|
|                         | Compounded suspension – check with local Pharmacy..  |
| <b>Excipients</b>       | <p>Lasix: sodium chloride, sodium hydroxide, water for injections (contains 0.16 mmol/mL of sodium).<br/>         Lasix High Dose Concentrate: Mannitol, sodium hydroxide, water for injections (contains 0.03 mmol/mL of sodium).<br/>         Furosemide-Baxter: sodium chloride, sodium hydroxide, hydrochloric acid, water for injections.<br/>         Lasix Oral Solution (refrigerated): sorbitol, glycerol, sodium hydroxide, methyl hydroxybenzoate, potassium sorbate, polysorbate 80, butylated hydroxytoluene, butylated hydroxyanisole, ethanol, Tetrarome Orange 987431 (PI 11335), quinoline yellow, purified water.<br/>         Lasix Oral Solution (not requiring refrigeration): sorbitol solution (70 per cent) (non-crystallising), glycerol, sodium hydroxide, methyl hydroxybenzoate, propyl hydroxybenzoate, ethanol, quinoline yellow, sunset yellow FCF, Trusil Orange Flavour 10814413 (PI 106046), purified water.</p>   |
| <b>Special comments</b> | <p>Loop diuretics are preferred for initial treatment of heart failure as they have a greater effect on sodium excretion compared to distal diuretics.<sup>2</sup><br/>         Potassium deficits can be corrected by the short-term use of potassium supplements.<br/>         Concomitant administration of a potassium-retaining agent such as spironolactone can prevent potassium depletion in most infants taking a loop diuretic.<br/>         Alternate day dosing may be considered to reduce the risk of electrolyte and mineral abnormalities.<br/>         Plasma <math>t_{1/2}</math> of furosemide is 7.7–26.8 hours in neonates. It is longer in immature infants (mean <math>t_{1/2}</math> &gt; 20 hours).<sup>22</sup> The <math>t_{1/2}</math> is prolonged by renal and hepatic insufficiency.<br/>         Blood concentrations exceeding 0.05 mg/mL may be associated with ototoxicity.<br/>         Administration of high doses at a rate faster than 4 mg/minute may result in tinnitus, vertigo and deafness, especially when combined with other ototoxic drugs or in patients with severe renal impairment.</p>   |
| <b>Evidence</b>         | <p><b>Efficacy:</b></p> <p><b>Heart failure:</b> Controlled trials have demonstrated diuretics increase urinary sodium excretion and decrease physical signs of fluid retention in patients with HF. In short-term studies, diuretic therapy led to a reduction in jugular venous pressures, pulmonary congestion, peripheral oedema and body weight; all of which were observed within days of initiation of therapy. In intermediate-term studies, diuretics have been shown to improve cardiac function, symptoms and exercise tolerance in patients with HF. There have been no long-term studies of diuretic therapy in HF and thus, their effects on morbidity and mortality are not known.<sup>2</sup></p> <p><b>Preterm infants with or developing chronic lung disease (CLD):</b> In preterm infants &lt; 3 weeks of age developing CLD, furosemide administration has either inconsistent effects or no detectable effect. In infants &gt; 3 weeks of age with CLD, a single intravenous dose of 1 mg/kg of furosemide improves lung compliance and airway resistance for one hour. Chronic administration of furosemide improves both oxygenation and lung compliance. Routine or sustained use of systemic loop diuretics in infants with (or developing) CLD cannot be recommended based on current evidence.<sup>3</sup> (LOE II, GOR C)</p> <p><b>Aerosolised diuretics for preterm infants with (or developing) chronic lung disease:</b> In preterm infants &gt; 3 weeks with CLD, administration of a single dose of aerosolised furosemide improves pulmonary mechanics. In view of the lack of data from randomised trials concerning effects on important clinical outcomes, routine or sustained use of aerosolised loop diuretics in infants with (or developing) CLD cannot be recommended based on current evidence.<sup>4</sup> (LOE I GOR C)</p> <p><b>Term infants with transient tachypnoea:</b> Diuretics had no effect in the treatment of transient tachypnoea of the newborn.<sup>5</sup> (LOE I, GOR B)</p> <p><b>Preterm infants with respiratory distress (RDS):</b> There are no data to support routine administration of furosemide in preterm infants with RDS and it may increase the risk of developing a symptomatic patent ductus arteriosus.<sup>6</sup> (LOE I GOR B)</p> <p><b>Electively transfused preterm infants beyond the first week of life:</b> Furosemide resulted in a reduction in post transfusion <math>FiO_2</math> (0.29 versus 0.27) which may be clinically insignificant.<sup>7</sup> (LOE II, GOR C)</p> <p><b>Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants:</b> Use of furosemide in combination with indomethacin increased the incidence of acute renal failure and did not affect the PDA closure rate.<sup>8,9</sup> (LOE II, GOR C)</p> <p><b>Infants with post-haemorrhagic ventricular dilatation:</b> Diuretic therapy is neither effective nor safe in treating post-haemorrhagic ventricular dilatation.<sup>10</sup> (LOE I, GOR B)</p> <p><b>Continuous infusion versus intermittent administration of furosemide:</b> The safety and benefits of continuous infusion of furosemide is unclear.<sup>11–13</sup> In adults and children, no significant increase in urine output except for when loading dose administered prior to infusion.<sup>11</sup> (LOE I, GOR C)</p> |

|                        |   |
|------------------------|---|
|                        | <p><b>Pharmacokinetics:</b> Plasma <math>t_{1/2}</math> of furosemide is 7.7–26.8 hours in neonates. It is lower in immature infants (mean <math>t_{1/2}</math> &gt; 20 hours)<sup>22</sup>. Drug accumulation may occur with 12 hour dosing especially in infants &lt; 33 weeks PMA.<sup>14</sup> (LOE IV, GOR B)</p> <p>The bioavailability of oral furosemide markedly reduced in preterm infants – estimated at 20%<sup>15</sup> compared to ~60% in adults.<sup>16</sup> 94% is plasma protein bound.<sup>15</sup> (LOE IV GOR C)</p> <p>Furosemide is primarily cleared via renal secretion (60–70%).<sup>16</sup> Clearance is reduced in renal impairment.</p> <p><b>Safety:</b> Furosemide results in renal excretion of calcium, sodium, chloride and potassium.<sup>17</sup> Prolonged and high dose use of furosemide, especially in the context of other ototoxic treatments (including aminoglycosides), has been associated with ototoxicity.<sup>18–20</sup> Blood concentrations exceeding 0.05 mg/mL may be associated with ototoxicity.<sup>14</sup> (LOE III-2 GOR B). Prolonged furosemide treatment and treatment combined with acetazolamide is associated with nephrocalcinosis.<sup>10, 21</sup> (LOE I GOR B)</p> <p>Alternate day furosemide may be associated with a lower risk of electrolyte and mineral abnormalities.<sup>23</sup></p>  |
| <b>Practice points</b> |   |
| <b>References</b>      | <ol style="list-style-type: none"> <li>1. O'Reilly PH, Consensus Committee of the Society of Radionuclides in N. Standardization of the renogram technique for investigating the dilated upper urinary tract and assessing the results of surgery. <i>BJU Int.</i> 2003;91:239-43.</li> <li>2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al, American College of C, American Heart Association Task Force on Practice G, American College of Chest P, International Society for H, Lung T, Heart Rhythm S. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). <i>Circulation.</i> 2005;112:e154-235.</li> <li>3. Stewart A, Brion LP. Intravenous or enteral loop diuretics for preterm infants with (or developing) chronic lung disease. <i>Cochrane Database Syst Rev.</i> 2011:CD001453.</li> <li>4. Brion LP, Primhak RA, Yong W. Aerosolized diuretics for preterm infants with (or developing) chronic lung disease. <i>Cochrane Database Syst Rev.</i> 2006:CD001694.</li> <li>5. Kassab M, Khriesat WM, Anabrees J. Diuretics for transient tachypnoea of the newborn. <i>Cochrane Database Syst Rev.</i> 2015;11:CD003064.</li> <li>6. Stewart A, Brion LP, Soll R. Diuretics for respiratory distress syndrome in preterm infants. <i>Cochrane Database Syst Rev.</i> 2011:CD001454.</li> <li>7. Balegar VK, Kluckow M. Furosemide for packed red cell transfusion in preterm infants: a randomized controlled trial. <i>J Pediatr.</i> 2011;159:913-8.e1.</li> <li>8. Brion LP, Campbell DE. Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants. <i>Cochrane Database Syst Rev.</i> 2001:CD001148.</li> <li>9. Lee BS, Byun SY, Chung ML, Chang JY, Kim HY, Kim EA, Kim KS, Pi SY. Effect of furosemide on ductal closure and renal function in indomethacin-treated preterm infants during the early neonatal period. <i>Neonatology.</i> 2010;98:191-9.</li> <li>10. Whitelaw A, Kennedy CR, Brion LP. Diuretic therapy for newborn infants with posthemorrhagic ventricular dilatation. <i>Cochrane Database Syst Rev.</i> 2001:CD002270.</li> <li>11. Alqahtani F, Koulouridis I, Susantitaphong P, Dahal K, Jaber BL. A meta-analysis of continuous vs intermittent infusion of loop diuretics in hospitalized patients. <i>J Crit Care.</i> 2014;29:10-7.</li> <li>12. Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. <i>Cochrane Database Syst Rev.</i> 2005:CD003178.</li> <li>13. Wu MY, Chang NC, Su CL, Hsu YH, Chen TW, Lin YF, Wu CH, Tam KW. Loop diuretic strategies in patients with acute decompensated heart failure: a meta-analysis of randomized controlled trials. <i>J Crit Care.</i> 2014;29:2-9.</li> <li>14. Pacifici GM. Clinical pharmacology of the loop diuretics furosemide and bumetanide in neonates and infants. <i>Paediatr Drugs.</i> 2012;14:233-46.</li> <li>15. Peterson RG, Simmons MA, Rumack BH, Levine RL, Brooks JG. Pharmacology of furosemide in the premature newborn infant. <i>J Pediatr.</i> 1980;97:139-43.</li> <li>16. Van Wart SA, Shoaf SE, Mallikaarjun S, Mager DE. Population-based meta-analysis of furosemide pharmacokinetics. <i>Biopharm Drug Dispos.</i> 2014;35:119-33.</li> <li>17. Atkinson SA, Shah JK, McGee C, Steele BT. Mineral excretion in premature infants receiving various diuretic therapies. <i>J Pediatr.</i> 1988;113:540-5.</li> <li>18. Borradori C, Fawer CL, Buclin T, Calame A. Risk factors of sensorineural hearing loss in preterm infants. <i>Biol Neonate.</i> 1997;71:1-10.</li> </ol> |

|  |   |
|--|---|
|  | <p>19. Robertson CM, Alton GY, Bork KT, Joffe AR, Tawfik GC, Sauve RS, Moddemann DM, Ross DB, Rebeyka IM. Bilateral sensory permanent hearing loss after palliative hypoplastic left heart syndrome operation. <i>Ann Thorac Surg.</i> 2012;93:1248-53.</p> <p>20. Robertson CM, Tyebkhan JM, Peliowski A, Etches PC, Cheung PY. Ototoxic drugs and sensorineural hearing loss following severe neonatal respiratory failure. <i>Acta Paediatr.</i> 2006;95:214-23.</p> <p>21. Gimpel C, Krause A, Franck P, Krueger M, von Schnakenburg C. Exposure to furosemide as the strongest risk factor for nephrocalcinosis in preterm infants. <i>Pediatr Int.</i> 2010;52:51-6.</p> <p>22. Pacifici GM. Clinical Pharmacology of Furosemide in Neonates: A Review. <i>Pharmaceuticals</i> 2013;6:1094-1129.</p> <p>23. Rush MG, Engelhardt B, Parker RA, Hazinski TA. Double-blind, placebo-controlled trial of alternate-day furosemide therapy in infants with chronic bronchopulmonary dysplasia. <i>J Pediatr.</i> 1990;117:112-8.</p> <p>24. Micromedex. Furosemide. Accessed online on 17 May 2021.</p> <p>25. Australian Injectable drugs handbook. Furosemide. Accessed online on 17 May 2021.</p> <p>26. MIMS online. Accessed online on 17 May 2021.</p> |
|--|---|

| <b>VERSION/NUMBER</b>             | <b>DATE</b> |
|-----------------------------------|-------------|
| <b>Original 1.0</b>               | 18/07/2016  |
| <b>Version 2.0</b>                | 19/04/2018  |
| <b>Version 3.0</b>                | 17/05/2021  |
| <b>Current 3.0 (Minor errata)</b> | 27/11/2025  |
| <b>REVIEW</b>                     | 17/05/2026  |

**Authors Contribution**

|  |   |
|--|---|
| Original author/s                        | Srinivas Bolisetty, David Osborn  |
| Evidence Review                          | David Osborn  |
| Expert review                            |   |
| Nursing Review                           | Eszter Jozsa  |
| Pharmacy Review                          | Cindy Chen  |
| ANMF Group contributors                  | Nilkant Phad, Bhavesh Mehta, Rebecca Barzegar, Rebecca O’Grady, Mohammed Irfan Azeem, Susannah Brew, Thao Tran, Celia Cunha Brites, Kerrie Knox, Jutta van den Boom, Michelle Jenkins, Renae Gengaroli, Bryony Malloy, Samantha Hassall, Amber Seigel, Daniel Lee, Trong Tran, Tiffany Kwan, Charles Tian, Gloria Yoo, Asif Khaliq, Amy Porter, Lily Byun |
| Final editing and review of the original | Ian Whyte   |
| Electronic version                       | Thao Tran, Helen Huynh, Cindy Chen, Ian Callander   |
| Facilitator                              | Srinivas Bolisetty  |